Comparison of therapeutic effects of two type of cock-up splint carpal tunnel syndrome

Background and Objective: Carpal Tunnel Syndrome is the most common compression neuropathy which can cause mild, moderate and sever disability in patiens hands. The first standard treatment is to use Cock-up splint. This study was done to compare therapeutic effects of long (With MP Joint restriction) and short (without mp Joint restriction) Cock-up splint patients with Carpal Tunnel Syndrome. Materials and Methods: In this clinical trail study was done on 23 patients with mild and moderate Carpal Tunnel Syndrome in Shafa Yahyayian Hospital, Tehran, Iran. The diagnosis of Carpal Tunnel Syndrome in patients confirmed with electrodiagnostic method. In this study 23 Patients was treated with long & short cock-up splint in two groups. Group A (12 Patients) was treated by long Splint and group B (11) Patients was treated by short Splint for 4 weeks. Patients was evaluated by Semmes –Wein stein monofilaments, Two Point discrimination, Visual analog Scale (VAS), pinch and Grip Strength. Results: Both types of splints appear to be effective in decreasing CTS symptoms but long Splint more beneficial than Short splint. The results of SWMS, 2PD, Pinch & grip Strength in group A had higher significant difference than group B. (P<0.05). Two groups did not have significant difference in results of severity of pain according to VAS. Conclusion: This study revealed that long Cock-up Splint in comparision with short Cock-up splint demonestrate high efficasy in improving the signs of Carpal Tunnel Syndrome

MicroRNA-372 acts as a double-edged sword in human cancers

MicroRNAs (miRNAs or miRs) are non-coding, single-stranded, endogenous RNAs that regulate various biological processes, most notably the pathophysiology of many human malignancies. It process is accomplished by binding to 3′-UTR mRNAs and controlling gene expression at the post-transcriptional level. As an oncogene, miRNAs can either accelerate cancer progression or slow it down as a tumor suppressor. MicroRNA-372 (miR-372) has been found to have an abnormal expression in numerous human malignancies, implying that the miRNA plays a role in carcinogenesis. It is both increased and downregulated in various cancers, and it serves as both a tumor suppressor and an oncogene. This study examines the functions of miR-372 as well as the LncRNA/CircRNA-miRNA-mRNA signaling pathways in various malignancies and analyses its potential prognostic, diagnostic, and therapeutic implications

Screening of potential inhibitors of COVID-19 with repurposing approach via molecular docking

SARS-CoV-2 (COVID-19) is the causative organism for a pandemic disease with a high rate of infectivity and mortality. In this study, we aimed to assess the affinity between several available small molecule and proteins, including Abl kinase inhibitors, Janus kinase inhibitor, dipeptidyl peptidase 4 inhibitors, RNA-dependent RNA polymerase inhibitors, and Papain-like protease inhibitors, using binding simulation, to test whether they may be effective in inhibiting COVID-19 infection through several mechanisms. The efficiency of inhibitors was evaluated based on docking scores using AutoDock Vina software. Strong ligand–protein interactions were predicted among some of these drugs, that included: Imatinib, Remdesivir, and Telaprevir, and this may render these compounds promising candidates. Some candidate drugs might be efficient in disease control as potential inhibitors or lead compounds against the SARS-CoV-2. It is also worth highlighting the powerful immunomodulatory role of other drugs, such as Abivertinib that inhibits pro-inflammatory cytokine production associated with cytokine release syndrome (CRS) and the progression of COVID-19 infection. The potential role of other Abl kinase inhibitors, including Imatinib in reducing SARS-CoV and MERS-CoV viral titers, immune regulatory function and the development of acute respiratory distress syndrome (ARDS), indicate that this drug may be useful for COVID-19, as the SARS-CoV-2 genome is similar to SARS-CoV